Antisense oligonucleotides are a new class of pharmaceuticals that act by attenuating the actual production of disease-related proteins. In this manner, a commercially practical and effective dose is delivered directly to the target tissue. EPI 2010 was developed to attenuate the production of the Adenosine A1 receptor in the cells lining the lung. EpiGenesis has demonstrated the utility of EPI-2010 in attenuating the expression of the adenosine A1 receptor in several animal models of asthma, including the primate. Taisho is actively strengthening research and development of new products in the prescription drug field and considers collaborations with bio-companies as a part of such activities.
EpiGenesis is a pioneer in the area of respirable antisense oligonucleotides.
EPI-2010 offers the strong possibility of treating asthma effectively, and brings patients new benefits not available with currently available asthma drugs.